Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTLNASDAQ:COYANASDAQ:PRTANASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.53+4.1%$1.43$1.11▼$5.00$407.20M1.771.49 million shs970,141 shsCOYACoya Therapeutics$5.71+0.7%$5.98$4.65▼$10.24$95.50M0.4972,854 shs42,232 shsPRTAProthena$6.55-4.0%$9.80$6.47▼$25.42$352.57M0.11597,104 shs933,156 shsSANASana Biotechnology$2.00+2.0%$1.78$1.26▼$8.31$450.95M1.753.42 million shs3.06 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-3.92%+20.49%+2.08%-24.62%-62.02%COYACoya Therapeutics-3.24%-0.35%-0.70%-9.64%-31.69%PRTAProthena-6.45%-1.02%-26.67%-55.28%-68.50%SANASana Biotechnology-6.22%+10.11%+23.27%-35.95%-76.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics3.096 of 5 stars3.54.00.00.02.13.30.6COYACoya Therapeutics2.09 of 5 stars3.55.00.00.02.00.00.0PRTAProthena3.855 of 5 stars4.43.00.00.04.11.71.3SANASana Biotechnology2.43 of 5 stars3.41.00.00.02.83.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.32509.15% UpsideCOYACoya Therapeutics 3.00Buy$17.00197.72% UpsidePRTAProthena 2.88Moderate Buy$51.71689.53% UpsideSANASana Biotechnology 2.86Moderate Buy$10.80440.00% UpsideCurrent Analyst Ratings BreakdownLatest COYA, PRTA, AUTL, and SANA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/13/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$48.00 ➝ $30.005/9/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$80.00 ➝ $78.005/9/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/28/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/24/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.004/22/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/10/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/1/2025AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/27/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$9.01M45.19N/AN/A$0.64 per share2.39COYACoya Therapeutics$3.69M25.92N/AN/A$2.47 per share2.31PRTAProthena$137.94M2.56N/AN/A$10.46 per share0.63SANASana BiotechnologyN/AN/AN/AN/A$1.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$208.38M-$0.88N/AN/AN/AN/A-63.65%-36.54%N/ACOYACoya Therapeutics-$7.99M-$1.07N/AN/AN/AN/A-31.63%-27.76%N/APRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%N/ASANASana Biotechnology-$283.26M-$0.88N/AN/AN/AN/A-84.22%-44.97%N/ALatest COYA, PRTA, AUTL, and SANA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025COYACoya Therapeutics-$0.44-$0.44N/A-$0.44$2.63 million$257.88 million5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/8/2025Q1 2025SANASana Biotechnology-$0.22-$0.20+$0.02-$0.21N/AN/A3/20/2025Q4 2024AUTLAutolus Therapeutics-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 million3/18/2025Q4 2024COYACoya Therapeutics-$0.32-$0.18+$0.14-$0.18$0.10 million$0.20 million3/17/2025Q4 2024SANASana Biotechnology-$0.25-$0.23+$0.02-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A13.6913.69COYACoya TherapeuticsN/A15.3115.31PRTAProthenaN/A11.5211.52SANASana BiotechnologyN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%COYACoya Therapeutics39.75%PRTAProthena97.08%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%COYACoya Therapeutics9.80%PRTAProthena9.20%SANASana Biotechnology30.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.71 millionOptionableCOYACoya Therapeutics616.73 million14.70 millionNot OptionablePRTAProthena13053.83 million38.64 millionOptionableSANASana Biotechnology380225.48 million153.83 millionOptionableCOYA, PRTA, AUTL, and SANA HeadlinesRecent News About These CompaniesSecurities Lawsuit Alert: Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025May 20 at 4:20 PM | accessnewswire.comSANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 20 at 4:00 PM | globenewswire.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana BiotechnologyMay 20 at 2:08 PM | tmcnet.comLost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & KorsinskyMay 20 at 10:15 AM | accessnewswire.comSANA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANAMay 20 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANAMay 20 at 9:00 AM | prnewswire.comLost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025May 20 at 7:15 AM | accessnewswire.comSANA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!May 20 at 7:00 AM | accessnewswire.comLevi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming DeadlineMay 20 at 5:45 AM | prnewswire.comSANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors - Lead Plaintiff Deadline May 20, 2025May 19 at 6:15 PM | accessnewswire.comSANA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANAMay 19 at 6:00 PM | accessnewswire.comClass Action Filed Against Sana Biotechnology, Inc. (SANA) Over Securities Violations - Contact Levi & Korsinsky TodayMay 19 at 3:55 PM | markets.businessinsider.comSana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes TreatmentMay 19 at 3:40 PM | seekingalpha.comShareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, ...May 19 at 2:30 PM | gurufocus.comSana Biotechnology, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before ...May 19 at 2:30 PM | gurufocus.comClass Action Filed Against Sana Biotechnology, Inc. (SANA) Over Securities Violations - Contact Levi & Korsinsky TodayMay 19 at 1:30 PM | accessnewswire.comShareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights – SANAMay 19 at 1:20 PM | globenewswire.comSANA DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action – SANAMay 19 at 1:15 PM | globenewswire.comSana Biotechnology, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANAMay 19 at 1:04 PM | prnewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Sana Biotechnology, Inc. (SANA) Investors of May 20, 2025 DeadlineMay 19 at 11:00 AM | accessnewswire.comDimensional Fund Advisors LP Buys 478,596 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)May 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOYA, PRTA, AUTL, and SANA Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.53 +0.06 (+4.08%) Closing price 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Coya Therapeutics NASDAQ:COYA$5.71 +0.04 (+0.71%) Closing price 04:00 PM EasternExtended Trading$6.00 +0.29 (+4.99%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Prothena NASDAQ:PRTA$6.55 -0.27 (-3.96%) Closing price 04:00 PM EasternExtended Trading$6.61 +0.06 (+0.92%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Sana Biotechnology NASDAQ:SANA$2.00 +0.04 (+2.04%) Closing price 04:00 PM EasternExtended Trading$2.02 +0.02 (+1.00%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Cathie Wood Just Bought a New Stake in Taiwan Semiconductor Stock Super Micro Computer Stock Clears New Path Higher on Saudi Orders Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Why Carnival Could Be the Ultimate Non-Tech Growth Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
